ZA200205852B - Human heparanase-related polypeptide and nucleic acid. - Google Patents
Human heparanase-related polypeptide and nucleic acid. Download PDFInfo
- Publication number
- ZA200205852B ZA200205852B ZA200205852A ZA200205852A ZA200205852B ZA 200205852 B ZA200205852 B ZA 200205852B ZA 200205852 A ZA200205852 A ZA 200205852A ZA 200205852 A ZA200205852 A ZA 200205852A ZA 200205852 B ZA200205852 B ZA 200205852B
- Authority
- ZA
- South Africa
- Prior art keywords
- polypeptide
- polynucleotide
- diseases
- expression
- sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 98
- 229920001184 polypeptide Polymers 0.000 title claims description 96
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 96
- 108010037536 heparanase Proteins 0.000 title description 22
- 150000007523 nucleic acids Chemical class 0.000 title description 11
- 102000039446 nucleic acids Human genes 0.000 title description 10
- 108020004707 nucleic acids Proteins 0.000 title description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 51
- 102000040430 polynucleotide Human genes 0.000 claims description 51
- 239000002157 polynucleotide Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 30
- 239000013598 vector Substances 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 108010060309 Glucuronidase Proteins 0.000 claims description 9
- 102000053187 Glucuronidase Human genes 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004071 biological effect Effects 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims 3
- 108010038807 Oligopeptides Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 14
- 102100024025 Heparanase Human genes 0.000 description 13
- 150000001413 amino acids Chemical group 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 210000000260 male genitalia Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000023117 embryonic morphogenesis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polyethylene glycol) Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01166—Heparanase (3.2.1.166)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01139—Alpha-glucuronidase (3.2.1.139)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99125831 | 1999-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200205852B true ZA200205852B (en) | 2003-10-22 |
Family
ID=8239724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200205852A ZA200205852B (en) | 1999-12-23 | 2002-07-22 | Human heparanase-related polypeptide and nucleic acid. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20040161745A1 (no) |
| EP (1) | EP1244778A2 (no) |
| JP (1) | JP2003518381A (no) |
| KR (1) | KR20020062375A (no) |
| CN (1) | CN1413249A (no) |
| AU (1) | AU3013901A (no) |
| BG (1) | BG106842A (no) |
| BR (1) | BR0016703A (no) |
| CA (1) | CA2392703A1 (no) |
| CZ (1) | CZ20022147A3 (no) |
| EE (1) | EE200200353A (no) |
| HU (1) | HUP0203724A2 (no) |
| IL (1) | IL149506A0 (no) |
| MX (1) | MXPA02005077A (no) |
| NO (1) | NO20023015L (no) |
| PL (1) | PL362867A1 (no) |
| RU (1) | RU2002119561A (no) |
| SK (1) | SK8882002A3 (no) |
| WO (1) | WO2001048161A2 (no) |
| ZA (1) | ZA200205852B (no) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5033101A (en) * | 2000-02-24 | 2001-10-08 | Bayer Aktiengesellschaft | Regulation of human heparanase-like enzyme |
| GB0008912D0 (en) * | 2000-04-11 | 2000-05-31 | Janssen Pharmaceutica Nv | Mammalian heparanase |
| AU2001251278A1 (en) * | 2000-04-20 | 2001-11-07 | Pharmacia And Upjohn Company | Heparanase ii, a human heparanase paralog |
| AU2001287610A1 (en) * | 2000-07-12 | 2002-01-21 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas |
| FR2818131B1 (fr) * | 2000-12-14 | 2005-02-11 | Oreal | Composition cosmetique comprenant de l'heparanase |
| CN101311188B (zh) * | 2007-05-21 | 2010-12-29 | 中国人民解放军军事医学科学院生物工程研究所 | 人乙酰肝素酶的小分子多肽抑制剂 |
| CN101670115B (zh) * | 2009-07-31 | 2011-07-27 | 中国人民解放军第三军医大学 | 乙酰肝素酶与热休克蛋白的复合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6177545B1 (en) * | 1997-09-02 | 2001-01-23 | Insight Strategy & Marketing Ltd. | Heparanase specific molecular probes and their use in research and medical applications |
| CA2307830A1 (en) * | 1997-10-28 | 1999-05-06 | The Australian National University | Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
| WO2001000643A2 (en) * | 1999-06-25 | 2001-01-04 | Insight Strategy & Marketing Ltd. | Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase |
| EP1214423A1 (en) * | 1999-09-23 | 2002-06-19 | MERCK PATENT GmbH | Heparanase-2, a member of the heparanase protein family |
-
2000
- 2000-12-18 MX MXPA02005077A patent/MXPA02005077A/es unknown
- 2000-12-18 RU RU2002119561/13A patent/RU2002119561A/ru unknown
- 2000-12-18 JP JP2001548674A patent/JP2003518381A/ja active Pending
- 2000-12-18 IL IL14950600A patent/IL149506A0/xx unknown
- 2000-12-18 AU AU30139/01A patent/AU3013901A/en not_active Abandoned
- 2000-12-18 HU HU0203724A patent/HUP0203724A2/hu unknown
- 2000-12-18 EE EEP200200353A patent/EE200200353A/xx unknown
- 2000-12-18 WO PCT/EP2000/012909 patent/WO2001048161A2/en not_active Application Discontinuation
- 2000-12-18 BR BR0016703-7A patent/BR0016703A/pt not_active Application Discontinuation
- 2000-12-18 SK SK888-2002A patent/SK8882002A3/sk unknown
- 2000-12-18 CZ CZ20022147A patent/CZ20022147A3/cs unknown
- 2000-12-18 PL PL00362867A patent/PL362867A1/xx not_active Application Discontinuation
- 2000-12-18 EP EP00990789A patent/EP1244778A2/en not_active Withdrawn
- 2000-12-18 CN CN00817680A patent/CN1413249A/zh active Pending
- 2000-12-18 US US10/168,795 patent/US20040161745A1/en not_active Abandoned
- 2000-12-18 CA CA002392703A patent/CA2392703A1/en not_active Abandoned
- 2000-12-18 KR KR1020027008186A patent/KR20020062375A/ko not_active Application Discontinuation
-
2002
- 2002-06-19 BG BG106842A patent/BG106842A/xx unknown
- 2002-06-21 NO NO20023015A patent/NO20023015L/no not_active Application Discontinuation
- 2002-07-22 ZA ZA200205852A patent/ZA200205852B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2002119561A (ru) | 2004-02-10 |
| CN1413249A (zh) | 2003-04-23 |
| KR20020062375A (ko) | 2002-07-25 |
| BG106842A (en) | 2003-05-30 |
| JP2003518381A (ja) | 2003-06-10 |
| IL149506A0 (en) | 2002-11-10 |
| US20040161745A1 (en) | 2004-08-19 |
| WO2001048161A2 (en) | 2001-07-05 |
| NO20023015D0 (no) | 2002-06-21 |
| WO2001048161A3 (en) | 2002-02-14 |
| CZ20022147A3 (cs) | 2002-09-11 |
| SK8882002A3 (en) | 2002-11-06 |
| AU3013901A (en) | 2001-07-09 |
| EP1244778A2 (en) | 2002-10-02 |
| MXPA02005077A (es) | 2002-11-07 |
| BR0016703A (pt) | 2002-09-24 |
| HUP0203724A2 (hu) | 2003-03-28 |
| PL362867A1 (en) | 2004-11-02 |
| EE200200353A (et) | 2003-10-15 |
| NO20023015L (no) | 2002-06-21 |
| CA2392703A1 (en) | 2001-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bernards et al. | The ltk receptor tyrosine kinase is expressed in pre‐B lymphocytes and cerebral neurons and uses a non‐AUG translational initiator. | |
| CN1270634A (zh) | 脊椎动物端粒酶基因和蛋白质及其用途 | |
| JPH08502885A (ja) | Ｐｔｐ １ｄ：新規なタンパク質チロシンホスファターゼ | |
| US6376661B1 (en) | Human RNase H and compositions and uses thereof | |
| ZA200205852B (en) | Human heparanase-related polypeptide and nucleic acid. | |
| JP2002502611A (ja) | ヒトヘパラナーゼポリペプチドおよびｃＤＮＡ | |
| JP2002355056A (ja) | 脈管形成を伴う障害の診断及び治療のための組成物及び方法 | |
| US20050282251A1 (en) | Heparanase II, a novel human heparanase paralog | |
| AU6327396A (en) | A c5a-like seven transmembrane receptor | |
| US6872558B1 (en) | Heparanase-2 a member of the heparanase protein family | |
| US20020155535A1 (en) | Novel human cysteine protease | |
| US5637462A (en) | Cathepsin C homolog | |
| WO1997006262A1 (en) | Non-receptor type human protein tyrosine phosphatase | |
| JP2002535962A (ja) | Ｃａｒｋ核酸分子およびその使用 | |
| US7195926B1 (en) | Antibodies to a cathepsin C homolog | |
| US20030144496A1 (en) | Human RNase H and compositions and uses thereof | |
| JP2005506838A (ja) | ヒトスルファターゼファミリーメンバーｍｉｄ９００２およびその使用 | |
| EP0857175A1 (en) | Novel human cysteine protease | |
| CN1978642A (zh) | 人hLDP基因序列、其编码蛋白及制备方法 | |
| MXPA98003196A (es) | Proteasa de cisteina humana novedosa | |
| CN1978646A (zh) | 人hNmrr基因序列、其编码蛋白及制备方法 | |
| WO2002004645A2 (en) | A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas | |
| MXPA97007852A (en) | Homologo de fosfolipas |